Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 45, Issue 7

Issues

Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy

Eric Bonnet
  • 1INSERM U563, Department of Lipoproteins and Lipid Mediators, CHU, Toulouse, France and Department of Infectious Diseases, Université Paul Sabatier, CHU, Toulouse, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Annelise Genoux / Jacques Bernard / Josette Fauvel / Patrice Massip / Bertrand Perret
Published Online: 2007-07-08 | DOI: https://doi.org/10.1515/CCLM.2007.140

Abstract

Active anti-HIV therapy can induce hypertriglyceridemia, low high-density lipoprotein (HDL) and insulin resistance, eventually accompanied by clinical lipodystrophy, associated loss of subcutaneous adipose tissue and an increase in abdominal adiposity. The frequency of these metabolic disorders is approximately 50% and host genetic factors might confer particular susceptibility. Variants of apolipoproteins (apo) A5 and C3, interacting with APOE genotypes, have been associated with the severity of antiretroviral therapy-induced dyslipidemia and with occurrence of lipodystrophy, and for APOC3, with objective criteria of fat redistribution. Genetic polymorphisms of the nuclear transcription-factor sterol response element-binding proteins (SREBP1c) and of tumor necrosis factor-α (TNFα) have yielded contrasting results. Other candidate genes will be explored to define a pharmacogenomic strategy to identify patients at high risk of metabolic disorders upon antiretroviral therapy.

Clin Chem Lab Med 2007;45:815–21.

Keywords: antiretroviral therapy; apolipoprotein A-V; apolipoprotein C-III; apolipoprotein E; dyslipidemia; HIV; lipodystrophy; pharmacogenomics; protease inhibitors; tumor necrosis factor-α (TNFα)

About the article

Corresponding author: Bertrand Perret, INSERM U563, bâtiment C, BP 3028, Hôpital Purpan, 31024 Toulouse Cédex 3, France Phone: +33-5-61779404, Fax: +33-5-61779401


Received: 2006-12-04

Accepted: 2007-01-15

Published Online: 2007-07-08

Published in Print: 2007-07-01


Citation Information: Clinical Chemical Laboratory Medicine, Volume 45, Issue 7, Pages 815–821, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: https://doi.org/10.1515/CCLM.2007.140.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Carlos A. Rocco, Debora Mecikovsky, Paula Aulicino, Rosa Bologna, Luisa Sen, Andrea Mangano, and Tom R. Gaunt
PLoS ONE, 2012, Volume 7, Number 7, Page e39678
[2]
Suraiya Rasheed, Jasper S. Yan, Alex Lau, Arvan S. Chan, and Douglas F. Nixon
PLoS ONE, 2008, Volume 3, Number 8, Page e3003
[3]
Denise Pui-Chung Chan, Man-Po Lee, Ngai-Sze Wong, Ross Ka-Kit Leung, Claire Melinda Naftalin, and Shui-Shan Lee
BMJ Open, 2016, Volume 6, Number 4, Page e010998
[4]
K Gedela, M Vibhuti, A Pozniak, B Ward, and M Boffito
HIV Medicine, 2014, Volume 15, Number 5, Page 257
[5]
Sirirat Likanonsakul, Tippawan Rattanatham, Siriluk Feangvad, Sumonmal Uttayamakul, Wisit Prasithsirikul, Somkid Srisopha, Ravee Nitiyanontakij, Pimrapat Tengtrakulcharoen, Maciej Tarkowski, Agostino Riva, Emi E. Nakayama, and Tatsuo Shioda
AIDS Research and Human Retroviruses, 2013, Volume 29, Number 1, Page 142
[6]
Andrea De Luca, Milena Nasi, Simona Di Giambenedetto, Alessandro Cozzi-Lepri, Marcello Pinti, Angela Marzocchetti, Cristina Mussini, Massimiliano Fabbiani, Laura Bracciale, Roberto Cauda, and Andrea Cossarizza
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2012, Volume 59, Number 2, Page 113
[7]
Gerard Aragonès, Carlos Alonso-Villaverde, Pedro Pardo-Reche, Anna Rull, Raúl Beltrán-Debón, Esther Rodríguez-Gallego, Laura Fernández-Sender, Jordi Camps, and Jorge Joven
BMC Medical Genetics, 2011, Volume 12, Number 1
[8]
Sergi Veloso, Montserrat Olona, Joaquim Peraire, Consuelo Viladés, Pedro Pardo, Pere Domingo, Victor Asensi, Montserrat Broch, Carmen Aguilar, Miguel López-Dupla, Gerard Aragonés, Graciano Garcia-Pardo, Joan-Josep Sirvent, Joan Vendrell, Cristóbal Richart, and Francesc Vidal, for the HIV Lipodystrophy St
AIDS Research and Human Retroviruses, 2011, Volume 27, Number 2, Page 143
[9]
Dr. Steven Kazmierczak
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 9
[10]
Barbara Zanone Poma, Agostino Riva, Milena Nasi, Paola Cicconi, Valentina Broggini, Alessandro Cozzi Lepri, Daniela Mologni, Francesco Mazzotta, Antonella DʼArminio Monforte, Cristina Mussini, Andrea Cossarizza, and Massimo Galli
AIDS, 2008, Volume 22, Number 14, Page 1769

Comments (0)

Please log in or register to comment.
Log in